| 查看: 3942 | 回复: 17 | |||||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||||
[交流]
达比加群酯的SWOT分析项
|
|||||
|
老大让我做一个SWOT分析，这对一个没有THOMSON、没有Pharmaproject的立项工作者来说，只能空手套白狼了，暂时只想出以下几个分析项，请各位虫友补充啦。 S分析 用药方法的便利性 出血安全性得到FDA、EMA等机构的屡次肯定 曾经获得FDA下属委员会全票支持 其对卒中的预防效果明显优于华法林 有间接比较研究显示，达比加群酯的成本-效益特征与有效性特征优于利伐沙班 先后在德国和加拿大被授予Prix Galien最佳药物奖 曾经获得NICE的有条件推荐 上市后市场表现强劲，已经实现了重磅炸弹级别的销售额 W分析 出血事件—达比加群酯挥之不去的阴影 肾功能损伤与P-gp是达比加群酯在其用药过程中需要调整剂量的主要因素 RE-ALLGN失败，使得人工心脏瓣膜成为达比加群酯的禁忌症之一 价格昂贵 O分析 适应证发病率高，用药市场规模庞大 需要开发新的药物，以弥补华法林的不足 利伐沙班于ROCKET-AF试验中仅证实与华法林相比的非劣性 T分析 将面临来自阿哌沙班、利伐沙班、依度沙班的激烈竞争 [ Last edited by williamxiang on 2013-4-3 at 16:31 ] |
回复此楼» 收录本帖的淘帖专辑推荐
 研发工艺 | 泮托拉唑 |
» 猜你喜欢
广西医科大学基础医学院自身免疫病课题组招收基础医学、药学和生物学等专业的研究生
已经有7人回复
-
[学习资料分享] FAERS数据库的不良反应挖掘(频数法/贝叶斯法)
已经有1人回复
-
药理学论文润色/翻译怎么收费?
已经有73人回复
-
招收医学、基础医学类调剂研究生
已经有0人回复
-
是否属于脾肾阳虚证
已经有0人回复
-
脑梗怎么治疗
已经有3人回复
-
脑梗怎么治疗
已经有0人回复
-
生物组织中有目标分析物，专属性怎么做
已经有0人回复
-
广西医科大学基础医学院自身免疫病课题组招收基础医学相关专业的调剂研究生
已经有2人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- 达比加群酯在中国获批
已经有17人回复
- 达比加群酯经过碱降解后产物会是什么结构？
已经有10人回复
- 达比加群酯甲磺酸盐 颜色
已经有10人回复
» 抢金币啦！回帖就可以得到:
-
【强推｜可留校】济南大学博士后招聘（水利工程/铁锰碳环境过程）
+1/287
-
【招聘】温州医科大学/附属医院/瓯江实验室李校堃院士团队诚聘博士后和科研人员
+1/191
-
五邑大学池振国教授团队2026年大量接收化学化工材料背景考研生
+5/120
-
山东建筑大学 （市政与环境工程学院）硕士研究生招生啦 静电纺丝纤维与盐水分离应用
+1/88
-
南方科技大学王鹏团队诚聘药物化学、化学探针、药物递送博士后
+1/79
-
合肥工科211水利工程调剂招生
+1/54
-
2026延安大学设施蔬菜环境调控与分子机制研究团队团队招收相关专业调剂研究生
+1/43
-
招聘︱国家纳米科学中心丁宝全杰青团队诚聘博士后（特别研究助理）
+2/42
-
欢迎化学、生物与医药、药学，生物、食品等相关专业的同学
+1/39
-
哈尔滨工业大学-大湾区大学2026年联合培养博士研究生春季招生-报名3月31号截至
+1/14
-
苏州初创公司诚聘化学过程工艺与硬件系统工程师
+1/10
-
天津理工大学国家杰青王铁团队招聘学术骨干、博士后
+1/8
-
北京石油化工学院VOCs净化技术课题组 招收2026级硕士调剂
+1/7
-
0854工学-电子信息考研-302分求调剂，接受跨专业，只求有学上！！！ ! ! ! ！
+1/4
-
基于机器学习和人工智能的结构/合金设计-西安交大
+1/4
-
长江师范学院化学化工学院2026年硕士研究生接收调剂的通知
+1/4
-
天津工业大学双一流高校招博士、硕士、博士后
+1/3
-
天津大学利物浦福州联合学院中外合办硕士【首批offer已发出】
+1/3
-
天津大学福州校区｜学长推荐上岸新思路
+1/1
-
考研292求调剂
+1/1
★ ★ ★ ★ ★ ★
小木虫: 金币+0.5, 给个红包，谢谢回帖
williamxiang: 金币+5 2013-04-03 10:47:53
小木虫: 金币+0.5, 给个红包，谢谢回帖
williamxiang: 金币+5 2013-04-03 10:47:53
|
Weaknesses A superiority claim over warfarin in stroke prevention was rejected for inclusion in the label by the FDA A 110 mg doseage was not approved for use in patients at higher bleeding risk A higher risk of myocardial infarction was seen in RE-LY Twice daily dosing, compared with once daily for Xarelto Not approved in the US for VTE prevention post-surgery, unlike Xarelto which was approved in July 2011 Has faced some safety concerns, and the label was updated to mandate renal testing in high-risk patients Associated with a 6% rate of major gastrointestinal hemorrhage during each patient year on treatment Other gastrointestinal side effects, including dyspepsia, nausea and gastritis, are increased compared with warfarin (35% vs 24%) Current lack of antidote Very short half-life once removed from specially designed desiccant-containing packaging |
3楼2013-04-03 10:41:12
★ ★ ★
小木虫: 金币+0.5, 给个红包，谢谢回帖
痴夷子皮: 金币+2, 谢谢交流，欢迎常来哦。 2013-04-07 08:32:18
小木虫: 金币+0.5, 给个红包，谢谢回帖
痴夷子皮: 金币+2, 谢谢交流，欢迎常来哦。 2013-04-07 08:32:18
|
Strengths The first novel anticoagulant to secure approval for stroke prevention in atrial fibrillation (AF), entering the US market in November 2010 No requirement for anticoagulation monitoring and dose adjustment, and no food effect In the RE-LY trial in AF, Pradaxa showed comparable to superior efficacy in stroke prevention, compared with warfarin, with equal to lower bleeding risk A subgroup analysis from RE-LY showed that Pradaxa 150 mg bid reduced the rate of stroke by 35% compared with well-controlled warfarin, irrespective of a patient's stroke risk Comparable to Lovenox in the prevention of major venous thromboembolism (VTE) and VTE-related mortality after both knee and hip replacement, according to RE-NOVATE data Equal efficacy to well-controlled warfarin in the treatment of acute VTE, but with a 37% reduction in major or clinically relevant bleeding risk over 6 months, according to RECOVER data |
2楼2013-04-03 10:38:46
★
小木虫: 金币+0.5, 给个红包，谢谢回帖
小木虫: 金币+0.5, 给个红包，谢谢回帖
|
Opportunities Approval in AF opens up a blockbuster market, and Pradaxa could garner a greater share of the market in the near term due to its first mover advantage Pradaxa could be viewed as superior to Xarelto given Xarelto's lack of superiority to warfarin on an intent-to-treat basis seen in the ROCKET AF trial Despite the proven efficacy of warfarin in stroke prevention, it has a number of limitations, such as an increased risk of bleeding and the need for patient monitoring and dose adjustment, which has created an unmet need for safe and effective alternatives Approval in acute coronary syndrome (ACS); phase III trials in this setting began in December 2007 Development of competitor Eliquis in ACS was discontinued following high rates of bleeding in trials High cost and considerable copay required for Pradaxa may fade as insurers realize potential savings from increased avoidance of ischemic events and hospitalization AF is the most common sustained cardiac rhythm disturbance, and prevalence increases with age Up to 60% of cases of AF are caused by hypertension or coronary artery disease, which are increasing in prevalence in most Western societies ACS is the leading cause of death in the US and one of the most prevalent non-communicable diseases in the world |
4楼2013-04-03 10:53:35
★ ★ ★ ★
williamxiang: 金币+4 2013-04-03 13:01:31
williamxiang: 金币+4 2013-04-03 13:01:31
|
Threats Commercial threat from Eliquis; current phase III data appear to support a superiority claim over warfarin which would differentiate the product Increased competition in the oral anticoagulant category; the marketing battle between Pradaxa, Xarelto and Eliquis will be key In Japan, Lixiana is in development for stroke prevention in AF, and could present competition in this market following Pradaxa's launch in March 2011 The drug may not gain approval in ACS given concerns about bleeding If approved, use in ACS may be limited given the availability of new, more potent antiplatelet regimes, such as AstraZeneca's Brilinta, that improve outcomes with less increased bleeding Physicians may be reluctant to switch patients who are well controlled on warfarin to other treatment options Price: the significant price difference between Pradaxa and warfarin could present reimbursement issue Self administration of low-molecular-weight heparins out of hospital by patients with AF undergoing elective cardioversion is a promising approach that may result in cost savings Low-molecular-weight heparins, in particular enoxaparin which presents a generic and efficacious option for DVT treatment and prophylaxis following orthopedic surgery |
5楼2013-04-03 10:54:50
